- Conditions
- Acute Lymphobkastic Leukemia, Medication Adherence
- Interventions
- Educational Website, #AYAOSM
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
Location Directory
Clinical trials in Chicago, Illinois
This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
17795
Shown on this page
12
Local exact-city summaries
3780
Based on exact city/state matches in the local index.
Local exact-city recruiting
1995
Live official results below use the broader ClinicalTrials.gov location search.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1–12 of 17,795 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Institutions in Chicago
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Invasive Candidiasis
- Interventions
- therapy duration
- Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 120 Days and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more
- Conditions
- Anesthesia, Conduction
- Interventions
- FLIR ONE, Regional Anesthesia - Caudal Nerve Block
- Device · Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma Multiforme, Recurrent Glioblastoma
- Interventions
- TheraSphere GBM
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 6 more
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Pembrolizumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 220
- States / cities
- Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Sean Sachdev
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 347
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
- Conditions
- Cytomegalovirus Prophylaxis
- Interventions
- Letermovir
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
- Conditions
- High-Risk Neuroblastoma
- Interventions
- hu1418K322A + Temozolomide + Irinotecan
- Drug
- Lead sponsor
- Renaissance Pharma Ltd.
- Industry
- Eligibility
- 18 Months to 18 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Relapsing Multiple Sclerosis, Multiple Sclerosis
- Interventions
- No Intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 100 more
- Conditions
- Schizophrenia
- Interventions
- Xanomeline/Trospium Chloride, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 32
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more